Pieces of evidence have shown that cytoskeleton regulator RNA ( CYTOR ), a long noncoding RNA (lncRNA), played a pivotal role in development and progression of a variety of cancers. In contrast, further research is needed to study the clinical significance and the detailed mechanism of action of lncRNA- CYTOR in colorectal cancer (CRC). This study aimed to investigate the clinical significance of CYTOR in CRC prognosis and identify the relevant potential signaling pathways and underlying mechanism of competing endogenous RNA. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) indicated that the expression of CYTOR was significantly elevated in CRC tumor tissues and cell lines. Aberrant expression of CYTOR was significantly related to TNM stage, T stage, N stage, and perineural and venous invasions. Survival analysis indicated that high- CYTOR expression was associated with poor overall survival in CRC patients ( p = 0.0057), and multivariate analysis showed that high- CYTOR expression was an independent prognostic factor, which led to poor OS. In addition, bioinformatics analysis revealed that there were 18 microRNAs (miRNAs) interacted with CYTOR , and one of them, miR-3679-5p might collaborate with metastasis-associated in colon cancer-1 ( MACC1 ), which was selected for further analysis. Pearson correlation analysis showed a significant positive correlation between the expression levels of CYTOR and MACC1 . In conclusion, this study suggested that lncRNA-CYTOR played an important role in tumorigenesis and development through the CYTOR /miR-3679-5p/ MACC1 axis.
Aim: We aimed to evaluate the diagnostic and prognostic values of P4HAs in breast cancer (BC) patients. Materials & methods: Kaplan–Meier plotter was used to evaluate the prognostic values of P4HAs...
To explore the potential clinical and prognostic significance of Homo sapiens solute carrier family 35 member F2 (SLC35F2) in the context of lung adenocarcinoma (LUAD). The expression pattern of SLC35F2 in LUAD tissues and normal tissues was analyzed in The Cancer Genome Atlas (TCGA) datasets and validated in 12 pairs of fresh clinical LUAD tissues and their corresponding adjacent normal tissues using quantitative real-time PCR (qRT-PCR) and western blotting. Immunohistochemistry (IHC) was used to assess the protein expression of SLC35F2 in 60 paraffin-embedded LUAD tissues, and its associations with clinicopathological parameters were further examined. The prognostic significance of SLC35F2 mRNA expression was also evaluated using the Kaplan-Meier method, and Cox regression models in LUAD patients from the TCGA database. The potential utility of SLC35F2 as an indicator of recurrence or metastasis was explored through the follow-up of selected clinical LUAD cases. Lastly, gene set enrichment analysis (GSEA) was conducted to investigate the underlying biological mechanisms and signaling pathways. Bioinformatics analysis utilizing the TCGA database indicated that SLC35F2 mRNA exhibited heightened expression in LUAD tissues when compared to normal tissues. These findings were further substantiated through the examination of 12 pairs of clinical LUAD tissues and their corresponding adjacent normal tissues, employing qRT-PCR and western blotting techniques. IHC results from a cohort of 60 LUAD patients demonstrated an up-regulation of SLC35F2 in 38 out of 60 individuals (63.3 %), which exhibited a significant correlation with tumor size, lymph node metastasis, and clinical stage (all P < 0.05). Both the Kaplan-Meier curve and the Cox proportional hazard analyses indicated a strong association between the up-regulation of SLC35F2 mRNA expression and unfavorable overall survival (OS) in patients with LUAD, as observed in the TCGA datasets (P < 0.05). The follow-up findings from select clinical LUAD cases provided evidence that the expression of SLC35F2 could serve as a dependable biomarker for monitoring the recurrence or metastasis. Additionally, the GSEA highlighted the enrichment of apoptosis, adhesion, small cell lung cancer (SCLC), and p53 signaling pathways in the subgroup of LUAD patients with elevated SLC35F2 expression. SLC35F2 exhibited an up-regulated in both mRNA and protein expression, rendering it a valuable independent prognostic indicator for patients diagnosed with LUAD.
19 November 2015 in Biotechnology & Biotechnological Equipment
A mutational laccase gene MLcc1 was synthesized with modified codons, based on the codon bias of Pichia pastoris, in order to improve the thermal stability of Trametes versicolor laccase. The mutant gene was subcloned into the expression vector pGAPZαA and was transformed into P. pastoris strain X33. The mature protein consisted of 498 amino acids and contained a changed aspartate with proline at the 14th position of the native laccase (NLCC1). Under optimum conditions, the laccase activity reached 194.06 U/L after 54 h by high cell density fermentation in a 5 L fermenter. After incubation at pH 4.6 for 2 h, the recombinant enzyme MLCC1 retained 54.9% of its maximum activity, whereas the wild-type enzyme retained about 50% of its maximum activity. More than 20% of the residual activity was detected after up to 120 min at 90 °C for MLCC1, whereas less than 10% of the activity was retained for NLCC1.
12 September 2018 in Journal of Agricultural and Food Chemistry
Objective: This study aims to develop a model for long non-coding RNA (lncRNA) associated with cuproptosis and assess the efficacy of immunotherapy and chemotherapy in children with Wilms tumor (WT) based on individualized risk scores.Methods: Data was obtained from the online database. Cox proportional hazards analysis and LASSO Cox regression were employed to generate cuproptosis-related lncRNA signatures. Patients were classified into high- and low-risk groups and clinical outcomes were further analysed. Tumor mutation burden and immunoinfiltration were calculated and potential immunotherapy response was evaluated. The sensitivity of immunotherapy and chemotherapy was ultimately analyzed based on individual risk scores associated with cuproptosis.Results: A eight cuproptosis-related lncRNAs signature was established and high-risk group showed a worse prognosis than the low-risk group. This model showed a good diagnostic performance. Low-risk group displayed an elevated tumor immune dysfunction and was more sensitive to 13 drugs.Conclusion: The current study introduces a novel approach for predicting clinical prognosis and determining the appropriate therapy for patients with WT.